Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01074242
Other study ID # V260-037
Secondary ID 2010_012
Status Completed
Phase N/A
First received February 22, 2010
Last updated April 1, 2015
Start date September 2007
Est. completion date June 2013

Study information

Verified date April 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Observational

Clinical Trial Summary

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Rotateq through collecting the safety information according to the Re-examination Regulation for New Drugs.


Recruitment information / eligibility

Status Completed
Enrollment 3798
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Weeks to 32 Weeks
Eligibility Inclusion Criteria:

- Infants Who Are Vaccinated With Rotateq For The Prevention Of Rotavirus Gastroenteritis Within Local Labeling Will Be Included

Exclusion Criteria:

- Participants who are vaccinated with Rotateq before study start

- Participant who has a contraindication to Rotateq according to the local label

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Any Adverse Experience An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience. Up to 42 days after any Rotateq vaccination Yes
Primary Percentage of Participants With Any Adverse Drug Reaction An adverse drug reaction was an adverse experience for which a causal relationship to the study drug could not be ruled out Up to 42 days after any Rotateq vaccination Yes